Movano Inc. (NASDAQ:MOVE – Get Free Report) CTO Michael Aaron Leabman sold 3,593 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $7.26, for a total transaction of $26,085.18. Following the completion of the transaction, the chief technology officer owned 35,720 shares in the company, valued at approximately $259,327.20. This trade represents a 9.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Michael Aaron Leabman also recently made the following trade(s):
- On Friday, January 9th, Michael Aaron Leabman sold 783 shares of Movano stock. The shares were sold at an average price of $7.27, for a total transaction of $5,692.41.
- On Wednesday, January 7th, Michael Aaron Leabman sold 3,293 shares of Movano stock. The stock was sold at an average price of $7.34, for a total transaction of $24,170.62.
Movano Trading Down 6.9%
Shares of NASDAQ:MOVE traded down $0.52 during trading on Monday, reaching $6.97. The company had a trading volume of 24,936 shares, compared to its average volume of 32,819. The company has a fifty day moving average of $8.79 and a two-hundred day moving average of $7.57. The stock has a market capitalization of $5.82 million, a P/E ratio of -0.64 and a beta of 0.79. Movano Inc. has a 12 month low of $4.67 and a 12 month high of $58.76.
Institutional Investors Weigh In On Movano
An institutional investor recently bought a new position in Movano stock. Citadel Advisors LLC purchased a new position in Movano Inc. (NASDAQ:MOVE – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 49,262 shares of the technology company’s stock, valued at approximately $28,000. Citadel Advisors LLC owned about 5.94% of Movano as of its most recent SEC filing. Hedge funds and other institutional investors own 16.64% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Movano in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Movano to a “hold” rating in a research note on Saturday, December 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Movano currently has an average rating of “Sell”.
View Our Latest Research Report on Movano
Key Headlines Impacting Movano
Here are the key news stories impacting Movano this week:
- Positive Sentiment: Short interest fell in December: as of Dec. 31 short interest dropped to 43,438 shares (‑29.1% vs Dec. 15). That represented roughly 5.8% of shares sold short and a days-to-cover of about 0.5, which reduces immediate squeeze risk and can be viewed as a short‑term positive for the stock.
- Neutral Sentiment: January short-interest report flagged a “significant increase” as of Jan. 12 but the published figures show 0 shares and an NaN change — an internal data/reporting inconsistency. Investors should treat this as unresolved data; a confirmed rise in short interest would be bearish, but the current entry looks like a reporting error and warrants watching for corrected filings.
- Negative Sentiment: Underlying fundamentals remain weak: most recent quarterly results showed a smaller-than-expected EPS loss but revenue was essentially negligible relative to estimates and the company reported extreme negative margins and return on equity. Those results underscore continued cash-burn and revenue execution risk for this very small‑cap company.
- Negative Sentiment: Low market cap and thin liquidity amplify moves: Movano’s market capitalization and average volume are small, so headline-driven flows (shorting, data corrections, or small trades) can produce outsized price swings. That structural risk likely contributes to the downward pressure today.
Movano Company Profile
Movano Health, Inc (NASDAQ: MOVE) is a health technology company focused on developing wearable devices for continuous biometric monitoring. The company’s core mission is to provide accessible, real-time health insights through noninvasive sensors, enabling individuals and care teams to track vital signs and physiological trends outside of traditional clinical settings.
Movano’s flagship product is a biometric monitoring ring designed to measure parameters such as heart rate, blood oxygen saturation, skin temperature, and sleep quality.
Featured Stories
- Five stocks we like better than Movano
- A month before the crash
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Trump’s Hand-Written Letter Will Shock his Haters
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for Movano Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Movano and related companies with MarketBeat.com's FREE daily email newsletter.
